International application No.
PCT/US04/34605

I .	SSIFICATION OF SUBJECT MATTER : A01N 1/00	•	
IPC(7) : A01N 1/00 US CL : 435/1.1, 1.2, 1.3			
According to International Patent Classification (IPC) or to both national classification and IPC			
B. FIELDS SEARCHED			
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/1.1, 1.2, 1.3			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched			
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, USPATFUL			
C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where	appropriate, of the relevant passages Relevant to claim No.	
Y	US 6,127,177 A (TONER et al.), 3 October 2000 (0		
Y	10. US 5,827,741 A (BEATTIE et al.) 27 October 1998	(27.10.1998), column 2, lines 33-46,	
х	column 7, line 49-column 8, line 3. US 2002/0076445 A1 (CROWE et al.) 20 June 2002	2 (20.06.2002), paragraph [0208].	
Further	documents are listed in the continuation of Day C		
Further documents are listed in the continuation of Box C. See patent family annex.			
	ecial categories of cited documents: defining the general state of the art which is not considered to be of relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
•	lication or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document establish th specified)	which may throw doubts on priority claim(s) or which is cited to ne publication date of another citation or other special reason (as	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is	
"O" document	referring to an oral disclosure, use, exhibition or other means	combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"P" document published prior to the international filing date but later than the priority date claimed		"&" document member of the same patent family	
Date of the actual completion of the international search Da		Date of mailing of the international search report	
28 October 2005 (28.10.2005)		1 09 NOV 2004	
Name and mailing address of the ISA/US		Authorized officer	
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450		Sandra Saucier Telephone No. (57) 272-0926	
Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201		100000000000000000000000000000000000000	

Form PCT/ISA/210 (second sheet) (April 2005)

International application No.

PCT/US04/34605

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)		
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:		
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:	
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:	
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)		
This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet		
1	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:	
4. Remark on I	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-6 Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.	
	The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.	
	No protest accompanied the payment of additional search fees.	

International application No. PCT/US04/34605

BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-6, drawn to a first method, a method of loading a disaccharide into mammalian nucleated cells.

Group II, claims 7-24, drawn to a second method, a method of increasing survival of mammalian nucleated cells following drying and rehydration comprising contacting the cells with a disaccharide.

Group III, claims 25-38, drawn to a third method, a method of increasing survival of mammalian nucleated cells following drying and rehydration comprising contacting the cells with an apoptosis inhibitor.

Group IV, claims 29-35, drawn to a fourth method, a method of increasing survival of mammalian nucleated cells following drying and rehydration comprising introducing or inducing production of a heat shock protein in the cells.

Group V, claims 36-37, drawn to a fifth method, a method of increasing survival of mammalian nucleated cells comprising incubating the cells with arbutin or hydroquinone.

Group VI, claims 38-43, drawn to a first composition comprising a mammalian nucleated cell, a disaccharide and arbutin or hydroquinone.

Group VII, claims 44-45, drawn to a second composition comprising a dried mammalian nucleated cell, a disaccharide and an exogenous heat shock protein.

Group VIII, claims 46-47, drawn to a third composition comprising a dried mammalian nucleated cell, a disaccharide and an exogenous apoptosis inhibitor.

The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

An international application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the of following combinations of categories;

- (1) a product and a process specially adapted for the manufacture of said product; or
- (2) a product and a process of use of said product; or
- (3) a product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) a process and an apparatus specifically designed for carrying out said process; or
- (5) a product, a process specially adapted for the manufacture of the said product and an apparatus specifically designed for carrying out said process. 37 CFR 1.475.

International application No. PCT/US04/34605

The groups of invention do not fall within any category. The product of Group VI contains a mammalian nucleated cell, a disaccharide and arbutin or hydroquinone. The process of Group V does not require the introduction of a disaccharide. Thus, the product of Group VI is not made by the process of Group V.

Likewise, the product of Group VII requires a disaccharide, an exogenous heat shock protein and a dried mammalian nucleated cell. The process of Group IV does not require the presence of a disaccharide. Thus, the composition of Group VII is not made by the process of Group IV.

Likewise, the product of Group VIII requires a dried mammalian nucleated cell, a disaccharide and an exogenous apoptosis inhibitor. The process of Group III does not require the presence of a disaccharide. Thus, the product of Group VIII is not made by the process of Group III.

PCT Rule 13 does not provide for multiple compositions or multiple methods of use or making within a single application. Thus, the first appearing composition is combined with a corresponding first method of use and the additional composition and method claims each constitute a separate group.